Get started
Author

Karen N. Bisnauthsing

Observed names: Bisnauthsing, Karen, K Bisnauthsing, K. Bisnauthsing, K.N. Bisnauthsing, Karen Bisnauthsing
Observed institutions: Guy's Hospital, University of Minnesota, St Thomas' Hospital, University of Leicester, Duke University, King's College London, Guy's and St Thomas' NHS Foundation Trust, Oxford Health NHS Foundation Trust, National Institute for Health and Care Research, University of Oxford, London School of Hygiene & Tropical Medicine, Duke Medical Center, Duke University Health System, Oxford University Hospitals NHS Trust, Centre for Inflammation Research, Bradford Teaching Hospitals NHS Foundation Trust, NIHR Leicester Biomedical Research Centre, Bradford Institute for Health Research, Imperial College London, University of Edinburgh
ORCID: 0000-0001-9045-1064
Observed ORCID: 0000-0001-9045-1064
OpenAlex ID: A5014033709
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
2020 · Merryn Voysey, Sue Ann Costa Clemens, et al. · The Lancet · 4,612
PDF
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
2020 · Jeffrey Seow, Carl Graham, et al. · Nature Microbiology · 1,421
PDF
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
2021 · Merryn Voysey, Sue Ann Costa Clemens, et al. · The Lancet · 1,118
PDF
A dynamic COVID-19 immune signature includes associations with poor prognosis
2020 · Adam G. Laing, Anna Lorenc, et al. · Nature Medicine · 943
PDF
Oral versus Intravenous Antibiotics for Bone and Joint Infection
2019 · Ho-Kwong Li, Ines Rombach, et al. · New England Journal of Medicine · 938
PDF
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study
2022 · R A Evans, O C Leavy, et al. · The Lancet Respiratory Medicine · 413
PDF
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial
2017 · Benoit Guery, Francesco Menichetti, et al. · The Lancet Infectious Diseases · 227
PDF
Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial
2017 · Guy E Thwaites, Matthew Scarborough, et al. · The Lancet · 199
PDF
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
2022 · Alasdair P S Munro, Shuo Feng, et al. · The Lancet Infectious Diseases · 175
PDF
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination
2021 · Angela M. Minassian, Sarah E. Silk, et al. · Med · 144
PDF
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
2022 · Felicity Liew, Shubha Talwar, et al. · EBioMedicine · 121
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease
2024 · Felicity Liew, Claudia Efstathiou, et al. · Nature Immunology · 107
PDF
Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings
2020 · Suzanne Pickering, Gilberto Betancor, et al. · PLoS Pathogens · 107
PDF
A cost benefit analysis of the Luminex xTAG Gastrointestinal Pathogen Panel for detection of infectious gastroenteritis in hospitalised patients
2014 · Simon D. Goldenberg, Mariana Bacelar, et al. · Journal of Infection · 100
Multiplex molecular testing for management of infectious gastroenteritis in a hospital setting: a comparative diagnostic and clinical utility study
2013 · E. Halligan, J. Edgeworth, et al. · Clinical Microbiology and Infection · 92
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
2022 · Karin Hardt, An Vandebosch, et al. · The Lancet Infectious Diseases · 83
PDF
Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis
2020 · Adam G. Laing, Anna Lorenc, et al. · Nature Medicine · 68
PDF
Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study
2023 · Betty Raman, Celeste McCracken, et al. · The Lancet Respiratory Medicine · 57
PDF
Universal hospital admission screening for carbapenemase-producing organisms in a low-prevalence setting
2016 · Jonathan A. Otter, Eleonora Dyakova, et al. · Journal of Antimicrobial Chemotherapy · 53
PDF
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41
PDF
Works count: 52
Citation count: 13,060
H-index: 29
I10-index: 43
Year
Topic
Type